Damora Therapeutics (DMRA) Equity Average (2019 - 2026)

Damora Therapeutics has reported Equity Average for 8 years, with the latest figure at $376.0 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 2445.64% year-over-year to $376.0 million; the trailing twelve-month figure through Mar 2026 stood at $376.0 million (up 2445.64% YoY), and the FY2025 full-year result was $128.1 million, up 431.98% from the prior year.
• Equity Average for Q1 2026 stood at $376.0 million, up from $124.2 million in the prior quarter.
• The five-year high for Equity Average was $376.0 million in Q1 2026, with the low at $9.5 million in Q3 2025.
• Historically, Equity Average has averaged $68.3 million across 5 years, with a median of $40.5 million in 2023.
• Annual changes were most pronounced in 2025 — Equity Average sank 57.42% — and 2026, when it jumped 2445.64%.
• Damora Therapeutics' Equity Average stood at $67.2 million in 2022, then plunged by 48.16% to $34.9 million in 2023, then slumped by 47.26% to $18.4 million in 2024, then surged by 575.59% to $124.2 million in 2025, then jumped by 202.75% to $376.0 million in 2026.
• The last three Equity Average figures came in at $376.0 million (Q1 2026), $124.2 million (Q4 2025), and $9.5 million (Q3 2025), per Business Quant data.